Will Elon Musk Buy a Nevada Lithium Mine?
With lithium prices so high, Elon Musk recently panic-tweeted about getting into the mining business to maintain his own Tesla battery metal supply. This lines up with the recent enactment of the Defense Production Act in March 2022 to ensure the strategic metals that are critical to the US and free world independence from China and Russia are produced in the US.
See the Latest Nevada Lithium Investing News
Frank A. D

Frank A. D'Amelio Insider Information

EVP of Pfizer
Frank A. D'Amelio is on the board of Humana, Inc., Zoetis, Inc. (former Chairman), Independent College Fund of New Jersey and The Gillen Brewer School. In the past he occupied the position of Chief Financial Officer & EVP-Global Supply at Pfizer Inc., Principal at AT&T, Inc., Chief Operating Officer & Director at Lucent Technologies, Inc., Chief Administrative Officer & SEVP-Integration at Alcatel-Lucent SAS, Chief Administrative Officer & Senior Executive VP at Nokia of America Corp. and Principal at Bell Laboratories.

Mr. D'Amelio received an undergraduate degree from Saint Peter's University and an MBA from St. John's University.

What is Frank A. D'Amelio's net worth?

The estimated net worth of Frank A. D'Amelio is at least $24.81 million as of July 2nd, 2019. Mr. D'Amelio owns 489,647 shares of Pfizer stock worth more than $24,805,517 as of June 29th. This net worth estimate does not reflect any other investments that Mr. D'Amelio may own. Learn More about Frank A. D'Amelio's net worth.

How do I contact Frank A. D'Amelio?

The corporate mailing address for Mr. D'Amelio and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323. Learn More on Frank A. D'Amelio's contact information.

Has Frank A. D'Amelio been buying or selling shares of Pfizer?

Frank A. D'Amelio has not been actively trading shares of Pfizer over the course of the past ninety days. As far as recent transactions, 0 shares of the business's stock in a transaction on Wednesday, June 29th. Learn More on Frank A. D'Amelio's trading history.

Who are Pfizer's active insiders?

Pfizer's insider roster includes Ronald Blaylock (Director), Loretta Cangialosi (VP), William Carapezzi, Jr. (EVP), Frank D'Amelio (EVP), Jennifer Damico (SVP), Jennifer Damico (SVP), Rady Johnson (Insider), Douglas Lankler (EVP), Alexander Mackenzie (EVP), Laurie Olson (Insider), Ian Read (CEO), Dawn Rogers (EVP), Sally Susman (Insider), and John Young (Insider). Learn More on Pfizer's active insiders.

Are insiders buying or selling shares of Pfizer?

In the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 276,647 shares worth more than $14,190,373.18. The most recent insider tranaction occured on June, 7th when SVP Jennifer B Damico sold 4,218 shares worth more than $227,603.28. Insiders at Pfizer own 0.1 % of the company. Learn More about insider trades at Pfizer.

Information on this page was last updated on 6/7/2022.

Frank A. D'Amelio Insider Trading History at Pfizer

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/2/2019Sell153,184$44.09$6,753,882.56489,647View SEC Filing Icon  
8/1/2018Sell150,484$40.00$6,019,360.00337,391View SEC Filing Icon  
8/31/2017Sell94,409$34.00$3,209,906.00337,389View SEC Filing Icon  
5/26/2016Sell100,000$34.49$3,449,000.00472,994View SEC Filing Icon  
5/10/2016Sell192,000$33.66$6,462,720.00564,994View SEC Filing Icon  
5/3/2016Sell87,079$33.65$2,930,208.35372,994View SEC Filing Icon  
2/11/2015Sell14,800$34.30$507,640.00View SEC Filing Icon  
See Full Table

Frank A. D'Amelio Buying and Selling Activity at Pfizer

This chart shows Frank A Damelio's buying and selling at Pfizer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pfizer Company Overview

Pfizer logo
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Read More

Today's Range

Now: $50.66
Low: $50.41
High: $51.97

50 Day Range

MA: $50.49
Low: $46.53
High: $53.99

2 Week Range

Now: $50.66
Low: $38.82
High: $61.71


16,458,770 shs

Average Volume

29,501,258 shs

Market Capitalization

$284.25 billion

P/E Ratio


Dividend Yield



US Govt. Injects $100's of Millions Into Lithium
The government's cash infusion could send lithium exploration companies soaring. They're desperate for new lithium mines to end China's Lithium Monopoly. See how you could take advantage of this enormous cash infusion.
Click Here To Read The Full Story